Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results von Cortes, Jorge E., Douglas Smith, B., Wang, Eunice S., Merchant, Akil, Oehler, Vivian G., Arellano, Martha, DeAngelo, Daniel J., Pollyea, Daniel A., Sekeres, Mikkael A., Robak, Tadeusz, Ma, Weidong Wendy, Zeremski, Mirjana, Naveed Shaik, M., Douglas Laird, A., O'Connell, Ashleigh, Chan, Geoffrey, Schroeder, Mark A.

Volltext

Eliminating Cancer Stem Cells by Targeting Embryonic Signaling Pathways von Oren, Ohad, Smith, B Douglas

Volltext

Phase I Study of Alvocidib Followed by 7+3 (Cytarabine plus Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia von Zeidner, Joshua F., Lee, Daniel J., Frattini, Mark, Fine, Gil D., Costas, Judy, Kolibaba, Kathryn, Anthony, Stephen P., Bearss, David, Smith, B. Douglas

Volltext

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo von Sato, Takashi, Yang, Xiaochuan, Knapper, Steven, White, Paul, Smith, B. Douglas, Galkin, Steven, Small, Donald, Burnett, Alan, Levis, Mark

Volltext

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease von Luznik, Leo, Bolaños-Meade, Javier, Zahurak, Marianna, Chen, Allen R., Smith, B. Douglas, Brodsky, Robert, Huff, Carol Ann, Borrello, Ivan, Matsui, William, Powell, Jonathan D., Kasamon, Yvette, Goodman, Steven N., Hess, Allan, Levitsky, Hyam I., Ambinder, Richard F., Jones, Richard J., Fuchs, Ephraim J.

Volltext

Overcoming microenvironment-mediated protection from ATRA using CYP26-resistant retinoids von Hernandez, Daniela, Palau, Laura, Norsworthy, Kelly, Anders, Nicole M., Alonso, Salvador, Su, Meng, Petkovich, Martin, Chandraratna, Rosh, Rudek, Michelle A., Smith, B. Douglas, Jones, Richard J., Ghiaur, Gabriel

Volltext

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure von Zeidan, Amer M, Knaus, Hanna A, Robinson, Tara M, Towlerton, Andrea M H, Warren, Edus H, Zeidner, Joshua F, Blackford, Amanda L, Duffield, Amy S, Rizzieri, David, Frattini, Mark G, Levy, Yair M, Schroeder, Mark A, Ferguson, Anna, Sheldon, Katherine E, DeZern, Amy E, Gojo, Ivana, Gore, Steven D, Streicher, Howard, Luznik, Leo, Smith, B Douglas

Volltext

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia von Pratz, Keith W, Rudek, Michelle A, Gojo, Ivana, Litzow, Mark R, McDevitt, Michael A, Ji, Jiuping, Karnitz, Larry M, Herman, James G, Kinders, Robert J, Smith, B Douglas, Gore, Steven D, Carraway, Hetty E, Showel, Margaret M, Gladstone, Douglas E, Levis, Mark J, Tsai, Hua-Ling, Rosner, Gary, Chen, Alice, Kaufmann, Scott H, Karp, Judith E

Volltext

Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS von Zeidner, Joshua F., Knaus, Hanna A., Zeidan, Amer M., Blackford, Amanda L., Montiel-Esparza, Raul, Hackl, Hubert, Prince, Gabrielle T., Gondek, Lukasz P., Ghiaur, Gabriel, Showel, Margaret M., DeZern, Amy E., Pratz, Keith W., Douglas Smith, B., Levis, Mark J., Gore, Steven, Coombs, Catherine C., Foster, Matthew C., Streicher, Howard, Karp, Judith E., Luznik, Leo, Gojo, Ivana

Volltext

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia von Gojo, Ivana, Beumer, Jan H, Pratz, Keith W, McDevitt, Michael A, Baer, Maria R, Blackford, Amanda L, Smith, B Douglas, Gore, Steven D, Carraway, Hetty E, Showel, Margaret M, Levis, Mark J, Dezern, Amy E, Gladstone, Douglas E, Ji, Jiuping Jay, Wang, Lihua, Kinders, Robert J, Pouquet, Marie, Ali-Walbi, Ismail, Rudek, Michelle A, Poh, Weijie, Herman, James G, Karnitz, Larry M, Kaufmann, Scott H, Chen, Alice, Karp, Judith E

Volltext

Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance von MATSUI, William, QIUJU WANG, WATKINS, D. Neil, HUFF, Carol Ann, JONES, Richard J, BARBER, James P, BRENNAN, Sarah, SMITH, B. Douglas, BORRELLO, Ivan, MCNIECE, Ian, LAN LIN, AMBINDER, Richard F, PEACOCK, Craig

Volltext

Age at Diagnosis and Patient Preferences for Treatment Outcomes in AML: A Discrete Choice Experiment to Explore Meaningful Benefits von Richardson, Daniel R., Crossnohere, Norah L., Seo, Jaein, Estey, Elihu, O'Donoghue, Bernadette, Smith, B. Douglas, Bridges, John F. P.

Volltext

Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias von KARP, Judith E, THOMAS, Brian M, MACKEY, Karen, FRESHWATER, Tomoko, LEVIS, Mark J, MCDEVITT, Michael A, CARRAWAY, Hetty E, GLADSTONE, Douglas E, SHOWEL, Margaret M, LOECHNER, Sabine, PARRY, David A, HOROWITZ, Jo Ann, GREER, Jacqueline M, ISAACS, Randi, KAUFMANN, Scott H, SORGE, Christopher, GORE, Steven D, PRATZ, Keith W, DOUGLAS SMITH, B, FLATTEN, Karen S, PETERSON, Kevin, SCHNEIDER, Paula

Volltext

Concise Review: Emerging Concepts in Clinical Targeting of Cancer Stem Cells von Rasheed, Zeshaan A., Kowalski, Jeanne, Smith, B. Douglas, Matsui, William

Volltext

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial von Heuser, Michael, Smith, B. Douglas, Fiedler, Walter, Sekeres, Mikkael A., Montesinos, Pau, Leber, Brian, Merchant, Akil, Papayannidis, Cristina, Pérez-Simón, José A., Hoang, Caroline J., O’Brien, Thomas, Ma, Weidong Wendy, Zeremski, Mirjana, O’Connell, Ashleigh, Chan, Geoffrey, Cortes, Jorge E.

Volltext

Outcome heterogeneity of TP53 -mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation von Pasca, Sergiu, Haldar, Saurav D, Ambinder, Alexander, Webster, Jonathan A, Jain, Tania, Dalton, W Brian, Prince, Gabrielle T, Ghiaur, Gabriel, DeZern, Amy E, Gojo, Ivana, Smith, B Douglas, Karantanos, Theodoros, Schulz, Cory, Stokvis, Kristin, Levis, Mark J, Jones, Richard J, Gondek, Lukasz P

Volltext

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies von Gupta, Mamta, Hendrickson, Andrea E. Wahner, Yun, Seong Seok, Han, Jing Jing, Schneider, Paula A., Koh, Brian D., Stenson, Mary J., Wellik, Linda E., Shing, Jennifer C., Peterson, Kevin L., Flatten, Karen S., Hess, Allan D., Smith, B. Douglas, Karp, Judith E., Barr, Sharon, Witzig, Thomas E., Kaufmann, Scott H.

Volltext

Intimate partner physical abuse perpetration and victimization risk factors: A meta-analytic review von Stith, Sandra M., Smith, Douglas B., Penn, Carrie E., Ward, David B., Tritt, Dari

Volltext

Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency von Hochman, Michael J., Smith, B. Douglas, Karantanos, Theodoros, Braunstein, Evan M., Gojo, Ivana, Jain, Tania, Streiff, Michael B., Moliterno, Alison R., DeZern, Amy E.

Volltext

Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management von Cortes, Jorge E., M.D, Jimenez, Carlos A., M.D, Mauro, Michael J., M.D, Geyer, Alex, M.D, Pinilla-Ibarz, Javier, M.D., Ph.D, Smith, B. Douglas, M.D

Volltext